Soufflé Therapeutics
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
$135MSeries B
ParticipantVV
Vida Ventures
Activity from announced rounds
Activity in this selectionUnited States
- Rounds participated in
- 5
- Confirmed lead rounds
- 0 4 roles undisclosed
- New companies
- 4 First participation on record · 1 follow-on
- Funding in participating rounds
- $432M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionInduPro
Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease
$77MSeries B
Role not disclosedSonoThera
Develops ultrasound-mediated nonviral genetic medicines
$125MSeries B
Role not disclosedPoplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$45MSeries A+
Role not disclosedPoplar Therapeutics
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
$50MSeries A
Role not disclosed